PT  - JOURNAL ARTICLE
AU  - Mori, Masahiro
AU  - Kuwabara, Satoshi
AU  - Fukutake, Toshio
AU  - Hattori, Takamichi
TI  - Intravenous immunoglobulin therapy for Miller Fisher syndrome
AID  - 10.1212/01.wnl.0000258673.31824.61
DP  - 2007 Apr 03
TA  - Neurology
PG  - 1144--1146
VI  - 68
IP  - 14
4099  - http://n.neurology.org/content/68/14/1144.short
4100  - http://n.neurology.org/content/68/14/1144.full
SO  - Neurology2007 Apr 03; 68
AB  - We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.